// App-Quantinova.ai

EP506 : ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA

Researchers

Presenter

  • Eva Domingo Domnech

Principal Investigators

  • Tim Illidge

  • Owen A. O'Connor

  • Barbara Pro

  • Swami P. Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Franck Morschhauser

  • Giuseppe Rossi

  • Won Seog Kim

  • Tatyana A. Feldman

  • Tobias Menne

  • David Belada

  • rpd Ills

  • Kensei Tobinai

  • Kunihiro Tsukasaki

  • Su-Peng Yeh

  • Andreas Httmann

  • Kerry J. Savage

  • Sam Yuen

  • Pier Luigi Zinzani

  • Harry Miao

  • Veronica Bunn

  • Keenan Fenton

  • Michelle A. Fanale

  • Markus Puhlmann

  • Lorenz Trmper

Medical Centers

  • Samsung Med Cntr, Korea, Republic of

  • E. Couric Cancer Center, University of Virginia,Charlottesville, VA,United States

  • Division of Oncology,Washington University School of Medicine in St. Louis,St. Louis,United States

  • Calvary Mater Newcastle Hospital, Waratan, Australia

  • Universitatsmedizin Gottingen, Gottingen, Germany

  • Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

  • Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford, CA

  • Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan

  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health,University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust,,Manchester,United Kingdom

  • Odense University Hospital, Odense, Denmark

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

  • Azienda AO Spedali Civili di Brescia, Brescia, Italy

  • Debreceni Egyetem,Debrecen,Hungary

  • Seagen Inc.,Bothell, WA,United States

  • Ovid Therapeutics New York NY United States

  • Divison of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

  • Hackensack University Medical Center, Oradell, NJ

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Division of Hematology and Oncology, Department of Internal Medicine,Kaohsiung Medical University Hospital,Kaohsiung city, Taiwan,Kaohsiung city,Taiwan, Province of China

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,Cambridge,United States

  • MD Anderson Cancer Center, The University of Texas, Houston, Texas, United States

  • CHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France

Locations

  • Republic of South Korea

  • United States

  • Australia

  • Germany

  • Japan

  • United Kingdom

  • Denmark

  • Czech Republic

  • Canada

  • Italy

  • Hungary

  • Spain

  • China

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multinational

Phase

  • III

Study Id's

  • NCT01777152

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved